|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, clinical negative correlations of miR-582-3p and miR-582-5p with SMAD2, SMAD4, TGFBRI, and TGFBRII were demonstrated in PCa tissues.
|
30852380 |
2019 |
|
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of Smad4, a well-known suppressive gene in PCa, can be increased by overexpression of hsa_circ_0001206 and this effect could be partly reversed by co-transfection of miR-1285-5p mimic.
|
31198063 |
2019 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the overexpression of miR-539-mediated DLX1 inhibition could potentially impede EMT, proliferation, migration and invasion of PCa cells through the blockade of the TGF-β/Smad4 signalling pathway, highlighting a potential miR-539/DLX1/TGF-β/Smad4 regulatory axis in the treatment of PCa.
|
31298493 |
2019 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hyperglycaemia-induced miR-301a promotes cell proliferation by repressing p21 and Smad4 in prostate cancer.
|
29331421 |
2018 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, <i>smad4/DPC4</i> is also mutated in other conditions and cancers such as juvenile polyposis syndrome with and without hereditary haemorrhagic telangiectasia, colorectal and prostate cancers.Immunohistochemistry for smad4/DPC4 protein is most useful in separating benign/reactive conditions from pancreatic cancer in needle/core biopsies.
|
29720405 |
2018 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Loss of Smad4 has also been found in human prostate cancer and drives tumorigenesis and metastasis when coupled with other genetic aberrations in mouse models.
|
29113300 |
2017 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, SENP1 deSUMOylated SMAD4 to promote EMT via up-regulating E-cadherin in prostate cancer cells.
|
28417919 |
2017 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
SMAD4 constrains progression of <i>Pten</i>-null prostate cancer and serves as a common downstream node of transforming growth factor β (TGFβ) and bone morphogenetic protein (BMP) pathways.
|
29352019 |
2017 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-331-3p-mediated miRNA maturation and enhanced EMT via effects on TGF-β/Smad 4 and Dicer are essential for the development of prostate cancer mediated by syndecan-1.
|
26259043 |
2016 |
|
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results indicated that the low expression of Smad4 mRNA in prostate cancer was associated with lymph node metastasis, preoperative prostate-specific antigen (PSA), and Gleason score.
|
24272204 |
2014 |
|
Malignant neoplasm of prostate
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The expression of sFRP1 and Smad4 was also modulated by genistein via DNA methylation or histone modifications in PC cell lines.
|
24504368 |
2014 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study provides rationale for investigation of HMMR, HOXC6, IGF1, MAP4K4, SIAH2, and SMAD4 as biomarkers of PCa aggressiveness in larger cohorts.
|
24708576 |
2014 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer.
|
23538390 |
2013 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Murine tumors show enrichment of the TGF-β/SMAD4 network, and genetic validation studies confirmed the cooperative roles of Pten, p53, and Smad4 deficiencies in prostate cancer progression, including skeletal metastases.
|
22341455 |
2012 |
|
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The functional relevance of SMAD4 was further supported by emergence of invasive, metastatic and lethal prostate cancers with 100% penetrance upon genetic deletion of Smad4 in the Pten-null mouse prostate.
|
21289624 |
2011 |
|
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This indicates that epigenetic changes affect the expression of the Smad4 protein in prostate cancer and points to methylation of the promoter as a novel marker of and contributor to the disease warranting further study.
|
18213629 |
2008 |
|
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nuclear p-Smad2 (P<0.001) and nuclear Smad4 (P=0.023) were significantly decreased in PC with remarkable variations in cytoplasmic Smad7 levels.
|
16550207 |
2006 |
|
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Given both the variability and lack of consensus reported regarding Smad4 expression in prostate cancer, we assessed Smad4 immunoreactivity in prostatic adenocarcinomas (PACs).
|
16260274 |
2005 |
|
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that decreased BMP2, nuclear smad8 and nuclear Smad4 expression are associated with the progression to PC, and in particular loss of BMP2 and Smad4 are related to progression to a more aggressive phenotype.
|
15042598 |
2004 |
|
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, only three (10%) of 29 informative primary prostate cancers showed allelic loss of chromosome 18q21 markers, and no point mutations or deletions of DPC4 were detected in the complete set of 45 primary or metastatic cases.
|
9285566 |
1997 |
|
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that inactivation of one or more putative tumor suppressor genes on 18q21 other than DCC and DPC4 plays an important role in the progression of human prostate cancer.
|
9331564 |
1997 |